Fig. 4
From: Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study
Efficacy of fremanezumab for quarterly patients. Patients received fremanezumab (225 mg) as the first dose and a quarterly dose of fremanezumab (675 mg) as the second dose. a Changes in MMD from baseline. *Significant difference compared with baseline. * adjusted p < 0.05; **adjusted p < 0.01; ***adjusted p < 0.001. Error bars represent 95% confidence interval. Abbreviations. MMD, monthly migraine days; 1 M, 1 month; 2 M, 2 months; 3 M, 3 months; 4 M, 4 months. b Responder rates. Proportion of patients with responder rates of 25, 50, 75, and 100